Efficacy of tadalafil treatment on erectile dysfunction in patients under dutasteride treatment: A prospective non-randomized comparative study

被引:5
作者
Ozkidik, Mete [1 ]
Gokce, Mehmet Ilker [1 ]
Yaman, Onder [1 ]
机构
[1] Ankara Univ, Dept Urol, Sch Med, Ankara, Turkey
来源
TURKISH JOURNAL OF UROLOGY | 2018年 / 44卷 / 04期
关键词
Dutasteride; erectile dysfunction; IIEF; tadalafil;
D O I
10.5152/tud.2018.46666
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: In this study, we aimed to evaluate the efficacy of tadalafil in the management of erectile dysfunction in patients under dutasteride medication for bladder outlet obstruction. Material and methods: In this study the data of consecutive patients that admitted to our outpatient clinics treated with dutasteride for bladder outlet obstruction and tadalafil (10 or 20 mg on demand) for concomitant complaint of erectile dysfunction (ED) between October 2013 and March 2016 were evaluated. An age-matched control group of patients treated with tadalafil for ED but did not receive any other medication for either lower urinary tract symptoms (LUTS) or ED was also included. Groups were compared for tadalafil efficacy with International Index of Erectile Function (IIEF) scores. Results: Each one of the dutasteride and control groups included 104 patients. The groups were similar for pretreatment IIEF score, serum cholesterol, low-density lipoprotein (LDL), triglyceride and testosterone measurements. The number of hypertensive patients was comparable between two groups but the number of diabetic patients were significantly higher in the control group. IIEF score improved significantly in both groups following tadalafil treatment but the difference between the two groups was not statistically significant. Conclusion: Tadalafil treatment provides significant improvement in erectile functions of patients under dutasteride treatment for bladder outlet obstruction. However, the current study does not focus on a population of dutasteride induced ED and therefore a further prospective study on this issue would be helpful.
引用
收藏
页码:294 / 297
页数:4
相关论文
共 10 条
[1]   Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor [J].
Clark, RV ;
Hermann, DJ ;
Cunningham, GR ;
Wilson, TH ;
Morrill, BB ;
Hobbs, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2179-2184
[2]   Tadalafil [J].
Curran, MP ;
Keating, GM .
DRUGS, 2003, 63 (20) :2203-2212
[3]   Sexual Function in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia: Results of a 6-Month, Randomized, Double-Blind, Placebo-Controlled Study of Tadalafil Coadministered with Finasteride [J].
Glina, Sidney ;
Roehrborn, Claus G. ;
Esen, Adil ;
Plekhanov, Alexey ;
Sorsaburu, Sebastian ;
Henneges, Carsten ;
Buettner, Hartwig ;
Viktrup, Lars .
JOURNAL OF SEXUAL MEDICINE, 2015, 12 (01) :129-138
[4]   EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction [J].
Gratzke, Christian ;
Bachmann, Alexander ;
Descazeaud, Aurelien ;
Drake, Marcus J. ;
Madersbacher, Stephan ;
Mamoulakis, Charalampos ;
Oelke, Matthias ;
Tikkinen, Kari A. O. ;
Gravas, Stavros .
EUROPEAN UROLOGY, 2015, 67 (06) :1099-1109
[5]   Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink [J].
Hagberg, Katrina Wilcox ;
Divan, Hozefa A. ;
Persson, Rebecca ;
Nickel, J. Curtis ;
Jick, Susan S. .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
[6]   Current use of phosphodiesterase inhibitors in urology [J].
Hakky, Tariq Said ;
Jain, Lakshay .
TURKISH JOURNAL OF UROLOGY, 2015, 41 (02) :88-92
[7]   The ENDOTRIAL Study: A Spontaneous, Open-Label, Randomized, Multicenter, Crossover Study on the Efficacy of Sildenafil, Tadalafil, and Vardenafil in the Treatment of Erectile Dysfunction [J].
Jannini, Emmanuele A. ;
Isidori, Andrea M. ;
Gravina, Giovanni Luca ;
Aversa, Antonio ;
Balercia, Giancarlo ;
Bocchio, Massimo ;
Boscaro, Marco ;
Carani, Cesare ;
Corona, Giovanni ;
Fabbri, Andrea ;
Foresta, Carlo ;
Forti, Gianni ;
Francavilla, Sandro ;
Granata, Antonio R. M. ;
Maggi, Mario ;
Mansani, Riccardo ;
Palego, Pierfrancesco ;
Spera, Giovanni ;
Vetri, Mario ;
Lenzi, Andrea .
JOURNAL OF SEXUAL MEDICINE, 2009, 6 (09) :2547-2560
[8]   Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials [J].
Liu, Luhao ;
Zhao, Shankun ;
Li, Futian ;
Li, Ermao ;
Kang, Ran ;
Luo, Lianmin ;
Luo, Jintai ;
Wan, Shawpong ;
Zhao, Zhigang .
JOURNAL OF SEXUAL MEDICINE, 2016, 13 (09) :1297-1310
[9]   Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia [J].
McVary, Kevin T. ;
Roehrborn, Claus G. ;
Avins, Andrew L. ;
Barry, Michael J. ;
Bruskewitz, Reginald C. ;
Donnell, Robert F. ;
Foster, Harris E., Jr. ;
Gonzalez, Chris M. ;
Kaplan, Steven A. ;
Penson, David F. ;
Ulchaker, James C. ;
Wei, John T. .
JOURNAL OF UROLOGY, 2011, 185 (05) :1793-1803
[10]   Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia [J].
Roehrborn, CG ;
Boyle, P ;
Nickel, JC ;
Hoefner, K ;
Andriole, G .
UROLOGY, 2002, 60 (03) :434-441